Business Wire

Clarity AI: Legacy Data Providers Have Discrepancies of More Than 20% in 13% of Direct Emissions Data

21.11.2022 09:00:00 CET | Business Wire | Press Release

Share

Clarity AI, the leading global sustainability tech platform, announced today that of approximately 6,500 public companies that report direct emissions, leading data providers have discrepancies in this reported data 42% of the time, where a discrepancy is any difference of more than 1%. When increasing the discrepancy threshold to more than 20%, leading data providers have discrepancies in one out of every eight data points.

“These significant discrepancies in 13% of the data can make the carbon footprint of a climate fund increase or decrease by more than 20% and highlight the real challenges that investors face when selecting a data provider,” said Patricia Pina, Head of Product Research and Innovation at Clarity AI. “Data reliability is core to what we do, and we see huge benefits in using advanced technology to help ensure quality.”

Clarity AI identified three problem areas legacy data providers can encounter when collecting data:

  1. Human Error: Human errors account for more than 80% of the errors found. These vary in nature but some examples include: incorrect addition of category values, misinterpretation of report details, and inaccurate unit measurements (e.g., tons vs. gigatons)
  2. Inconsistent Reporting Boundaries: Data providers use boundaries (i.e., rules to decide which entities from the group to include or not, what to do with joint ventures, investments, etc.) for emissions reporting inconsistently
  3. Incomplete Disclosures: Companies publish incomplete disclosures that omit relevant emissions (e.g., Scope 3 categories, regions/offices, business lines)

“At Clarity AI we rely on technology and data to solve reliability issues. First, we curate a robust dataset of sustainability data points, which have gone through rigorous quality checks. Then, we have trained, calibrated, and validated an expert-supervised machine learning model to select the most reliable data points and filter out non-reliable data,” added Ron Potok, Head of Data Science at Clarity AI. “The flexibility of a machine learning model allows for much more complex relationships between the reliability of a data point and its features. The model analyzes the data from all angles at every level of granularity, which boosts its performance.”

Advanced technology, like machine learning, is the only scalable and efficient way to create clean, reliable data that investors can rely on. Clarity AI has trained state-of-the-art machine learning algorithms leveraging input from sustainability experts and is the only sustainability tech provider in the market with a sophisticated machine learning reliability algorithm. Moreover, the algorithms and models only get better and better with time and continuous care from advanced technology experts, because when a data point is detected as non-reliable, it is sent for external review (i.e., to the team of experts) and corrected if necessary. Then, this data will enter back the system and further train and improve the model in a virtuous cycle.

—------------

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. As of August 2022, Clarity AI’s platform analyzes more than 50,000 companies, 320,000 funds, 198 countries, and 188 local governments – 2-13 times more than any other player in the market – and delivers data and analytics for investing, corporate research, benchmarking, consumer e-commerce and reporting. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets under management. clarity.ai

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Edelman
clarityAI@edelmansmithfield.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye